MetLife Investment Management’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-38,125
| Closed | -$4.89M | – | 2853 |
|
|
2025
Q2 | $4.89M | Buy |
38,125
+611
| +2% | +$63.5K | 0.03% | 582 |
|
|
2025
Q1 | $3.32M | Sell |
37,514
-585
| -2% | -$57.1K | 0.02% | 816 |
|
|
2024
Q4 | $3.32M | Buy |
38,099
+1,830
| +5% | +$168K | 0.02% | 786 |
|
|
2024
Q3 | $3.35M | Hold |
36,269
| – | – | 0.02% | 751 |
|
|
2024
Q2 | $3.91M | Buy |
36,269
+5,135
| +16% | +$514K | 0.02% | 632 |
|
|
2024
Q1 | $2.95M | Sell |
31,134
-1,182
| -4% | -$101K | 0.02% | 790 |
|
|
2023
Q4 | $2.98M | Hold |
32,316
| – | – | 0.02% | 773 |
|
|
2023
Q3 | $1.62M | Hold |
32,316
| – | – | 0.01% | 1000 |
|
|
2023
Q2 | $2.04M | Buy |
32,316
+534
| +2% | +$29K | 0.01% | 927 |
|
|
2023
Q1 | $1.43M | Hold |
31,782
| – | – | 0.01% | 1045 |
|
|
2022
Q4 | $1.39M | Hold |
31,782
| – | – | 0.01% | 1047 |
|
|
2022
Q3 | $2.09M | Hold |
31,782
| – | – | 0.02% | 852 |
|
|
2022
Q2 | $1.61M | Hold |
31,782
| – | – | 0.01% | 982 |
|
|
2022
Q1 | $2.03M | Buy |
31,782
+11,131
| +54% | +$799K | 0.01% | 983 |
|
|
2021
Q4 | $2.21M | Hold |
20,651
| – | – | 0.02% | 832 |
|
|
2021
Q3 | $2.12M | Hold |
20,651
| – | – | 0.02% | 838 |
|
|
2021
Q2 | $1.82M | Hold |
20,651
| – | – | 0.02% | 917 |
|
|
2021
Q1 | $2.01M | Sell |
20,651
-1,183
| -5% | -$118K | 0.02% | 867 |
|
|
2020
Q4 | $2.45M | Sell |
21,834
-2,044
| -9% | -$215K | 0.02% | 724 |
|
|
2020
Q3 | $2.21M | Hold |
23,878
| – | – | 0.02% | 675 |
|
|
2020
Q2 | $1.86M | Buy |
23,878
+1,373
| +6% | +$92.9K | 0.02% | 743 |
|
|
2020
Q1 | $1.32M | Buy |
22,505
+1,989
| +10% | +$128K | 0.02% | 787 |
|
|
2019
Q4 | $1.64M | Sell |
20,516
-1,255
| -6% | -$94K | 0.02% | 884 |
|
|
2019
Q3 | $1.6M | Hold |
21,771
| – | – | 0.02% | 869 |
|
|
2019
Q2 | $2.05M | Buy |
21,771
+3,965
| +22% | +$327K | 0.02% | 804 |
|
|
2019
Q1 | $1.43M | Hold |
17,806
| – | – | 0.02% | 943 |
|
|
2018
Q4 | $960K | Hold |
17,806
| – | – | 0.01% | 1031 |
|
|
2018
Q3 | $1.39M | Sell |
17,806
-1,562
| -8% | -$109K | 0.01% | 992 |
|
|
2018
Q2 | $1.23M | Hold |
19,368
| – | – | 0.01% | 942 |
|
|
2018
Q1 | $1.78M | Hold |
19,368
| – | – | 0.02% | 813 |
|
|
2017
Q4 | $1.46M | Buy |
+19,368
| New | +$1.36M | 0.02% | 880 |
|
Other funds holding BPMC
IA
HNB
MetLife Investment Management's BPMC Position: Q3 2025 in Review
MetLife Investment Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 38,125 shares — an estimated $4.89M sold.
MetLife Investment Management first reported a position in BPMC in Q4 2017 and held it in 31 quarters. The position peaked at $4.89M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- MetLife Investment Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- MetLife Investment Management sold 38,125 Blueprint Medicines shares in Q3 2025, an estimated $4.89M.
- MetLife Investment Management first reported a position in Blueprint Medicines in Q4 2017 and held it in 31 quarters.
- MetLife Investment Management's Blueprint Medicines position peaked at $4.89M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on MetLife Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.